Related Experiment Video
Updated: Aug 6, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates
Namasivayam Ambalavanan1, Zuzana E Novak
1Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA. ambal@srynet.com
Insights
Elevated basic fibroblast growth factor (bFGF) in preterm infant tracheal aspirates correlates with bronchopulmonary dysplasia (BPD) and cell injury. This peptide growth factor may play a role in BPD development.
Area of Science:
- Neonatal Research
- Pulmonary Medicine
- Biomedical Science
Background:
- Peptide growth factors (PGF) like bFGF, VEGF, and ET-1 are crucial for lung development and repair.
- These PGF may contribute to the pathogenesis of bronchopulmonary dysplasia (BPD), a common complication in preterm infants.
- Chorioamnionitis is a known risk factor for BPD.
Purpose of the Study:
- To investigate the association between elevated PGF levels in tracheal aspirates and BPD or death in preterm infants.
- To determine if PGF levels correlate with markers of cell injury, apoptosis, and chorioamnionitis.
- To explore the potential role of specific PGF in BPD pathogenesis.
Main Methods:
- Tracheal aspirates were collected from 29 preterm infants (<34 weeks gestation) on day 1 of life.
- Assays included ELISA for PGF and histone-associated DNA fragments (apoptosis marker), and enzyme assay for LDH (cell injury marker).
- Clinical and pathological examinations assessed chorioamnionitis; BPD was defined by oxygen/ventilation needs at 28 days.
Main Results:
- Eighteen infants died or developed BPD.
- Elevated bFGF levels were significantly associated with BPD or death (p=0.01).
- bFGF levels strongly correlated with apoptosis (r=0.73) and LDH (r=0.59). VEGF and ET-1 showed no significant association with BPD/death or apoptosis. PGF levels did not correlate with chorioamnionitis.
Conclusions:
- Elevated tracheal bFGF levels in preterm infants are linked to BPD/death and markers of cell injury and apoptosis.
- VEGF, ET-1, and chorioamnionitis were not found to be associated with these outcomes in this cohort.
- bFGF is a potential biomarker and may play a role in the pathophysiology of BPD.
Abstract:
Basic fibroblast growth factor (bFGF or FGF-2), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1) are peptide growth factors (PGF) mediating normal lung development, maturation, injury, and repair. These PGF may therefore be involved in the pathogenesis of bronchopulmonary dysplasia (BPD). We hypothesized that elevated levels of these PGF in tracheal aspirates would be associated with a) BPD and/or death; b) markers of cell injury and apoptosis; and c) chorioamnionitis, a risk factor for BPD. Tracheal aspirates collected in 29 preterm (<34 wk gestation, 500-2000 g birth weight), mechanically ventilated infants on d 1 of life were assayed for PGF and histone-associated DNA fragments by ELISA and for LDH by enzyme assay. Clinical and pathologic examination was performed for chorioamnionitis. BPD was defined as oxygen requirement/mechanical ventilation at 28 d postnatal age. The birth weight (mean +/- SE) was 1009 +/- 85 g and median gestational age was 26 wk (range, 22-33). Eighteen infants died or developed BPD. bFGF levels were elevated in infants who died or developed BPD [median (25%,75%) level of 36 (23, 44) pg/mL versus 14 (6, 30) in the survivors without BPD, p = 0.01]. bFGF levels correlated with apoptosis (r = 0.73, p < 0.001) and LDH levels (r = 0.59, p < 0.001). VEGF and ET-1 levels were not associated with apoptosis or with BPD/death. PGF levels were not associated with chorioamnionitis. We conclude that elevated bFGF levels in the preterm trachea correlate with BPD/death and markers of cell injury and apoptosis but not with chorioamnionitis. We speculate that bFGF may play a role in the development of BPD.
More Related Videos
Related Concept Videos
Breathing
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...

